EYPT
EyePoint Pharmaceuticals, Inc. NASDAQ Listed Jan 27, 2005$13.39
Mkt Cap $1.1B
52w Low $5.30
58.6% of range
52w High $19.11
50d MA $14.34
200d MA $13.81
P/E (TTM)
-4.2x
EV/EBITDA
-5.2x
P/B
3.2x
Debt/Equity
0.1x
ROE
-75.8%
P/FCF
-5.5x
RSI (14)
—
ATR (14)
—
Beta
1.91
50d MA
$14.34
200d MA
$13.81
Avg Volume
1.3M
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
480 Pleasant Street · Watertown, MA 02472 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 4, 2026 | BMO | -0.78 | -0.81 | -3.8% | 18.00 | -0.1% | -12.4% | -0.1% | -0.5% | -1.5% | -3.4% | — |
| Nov 5, 2025 | BMO | -0.77 | -0.85 | -10.4% | 11.02 | -0.9% | +0.5% | +1.2% | +1.2% | +2.6% | +2.9% | — |
| Aug 6, 2025 | BMO | -0.67 | -0.85 | -26.9% | 10.58 | +2.2% | -4.8% | +1.6% | +0.5% | +4.6% | +2.4% | — |
| May 7, 2025 | BMO | -0.65 | -0.65 | +0.0% | 6.09 | +0.0% | +0.2% | -4.8% | +0.7% | +1.0% | -7.1% | — |
| Mar 5, 2025 | BMO | -0.54 | -0.64 | -18.5% | 6.58 | -3.8% | +3.6% | +4.5% | -0.6% | +3.7% | -0.3% | — |
| Nov 7, 2024 | BMO | -0.48 | -0.54 | -12.5% | 11.59 | +0.0% | +0.3% | +3.2% | -7.4% | -3.2% | -2.5% | — |
| Aug 7, 2024 | BMO | -0.55 | -0.58 | -5.5% | 8.65 | +3.1% | +5.9% | -4.5% | -4.5% | -6.1% | -3.4% | — |
| May 8, 2024 | BMO | -0.34 | -0.55 | -61.8% | 11.56 | +6.7% | +9.6% | -4.6% | +1.1% | +1.9% | +3.9% | — |
| Mar 7, 2024 | BMO | -0.60 | -0.33 | +45.0% | 25.31 | -1.1% | -3.6% | -6.3% | -0.3% | -3.2% | -1.6% | — |
| Nov 1, 2023 | BMO | -0.62 | -0.33 | +46.8% | 7.24 | +5.0% | +0.7% | +6.3% | -1.5% | +0.3% | -8.6% | — |
| Aug 2, 2023 | BMO | 0.41 | -0.61 | -248.8% | 12.79 | +0.1% | -2.0% | +3.0% | -4.1% | +0.0% | +6.1% | — |
| May 3, 2023 | BMO | -0.65 | -0.56 | +13.8% | 7.90 | -1.4% | -14.2% | -3.5% | -1.1% | +0.5% | +2.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9 | Citigroup | Maintains | Buy → Buy | — | $15.75 | $15.58 | -1.1% | -0.5% | -1.5% | -3.4% | -6.0% | -5.9% |
| Mar 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.00 | $17.98 | -0.1% | -12.4% | -0.1% | -0.5% | -1.5% | -3.4% |
| Mar 4 | Chardan Capital | Maintains | Buy → Buy | — | $18.32 | $17.63 | -3.8% | -1.7% | -12.4% | -0.1% | -0.5% | -1.5% |
| Nov 6 | RBC Capital | Maintains | Outperform → Outperform | — | $11.02 | $10.92 | -0.9% | +0.5% | +1.2% | +1.2% | +2.6% | +2.9% |
| Aug 7 | Chardan Capital | Maintains | Buy → Buy | — | $10.58 | $10.81 | +2.2% | -4.8% | +1.6% | +0.5% | +4.6% | +2.4% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.89 | $9.82 | -9.8% | -2.8% | -4.8% | +1.6% | +0.5% | +4.6% |
| May 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.04 | $7.19 | +2.1% | +2.4% | +0.4% | +2.5% | +9.4% | +1.0% |
| May 16 | Mizuho | Maintains | Outperform → Outperform | — | $5.72 | $5.81 | +1.6% | +7.2% | -0.5% | +1.8% | -5.5% | -4.6% |
| May 8 | Chardan Capital | Maintains | Buy → Buy | — | $6.09 | $6.09 | +0.0% | +0.2% | -4.8% | +0.7% | +1.0% | -7.1% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.58 | $6.33 | -3.8% | +3.6% | +4.5% | -0.6% | +3.7% | -0.3% |
| Mar 6 | Chardan Capital | Maintains | Buy → Buy | — | $6.58 | $6.33 | -3.8% | +3.6% | +4.5% | -0.6% | +3.7% | -0.3% |
| Feb 6 | Chardan Capital | Maintains | Buy → Buy | — | $7.80 | $7.81 | +0.1% | -15.1% | -1.8% | -3.5% | +0.2% | +1.1% |
| Dec 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.49 | $8.43 | -0.7% | -3.9% | +6.7% | +1.6% | -4.4% | -2.5% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.63 | $11.73 | +0.9% | +3.2% | -7.4% | -3.2% | -2.5% | -12.6% |
| Nov 11 | Baird | Maintains | Outperform → Outperform | — | $11.63 | $11.73 | +0.9% | +3.2% | -7.4% | -3.2% | -2.5% | -12.6% |
| Nov 8 | Chardan Capital | Maintains | Buy → Buy | — | $11.59 | $11.59 | +0.0% | +0.3% | +3.2% | -7.4% | -3.2% | -2.5% |
| Oct 29 | Chardan Capital | Maintains | Buy → Buy | — | $12.12 | $12.02 | -0.8% | -4.8% | -0.7% | +2.6% | +2.6% | -3.0% |
| Oct 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.56 | $9.59 | +0.3% | -0.6% | +27.6% | -4.8% | -0.7% | +2.6% |
| Aug 13 | JP Morgan | Maintains | Overweight → Overweight | — | $8.36 | $8.48 | +1.4% | -6.1% | -3.4% | +8.2% | -3.3% | +0.1% |
| Jun 28 | Chardan Capital | Maintains | Buy → Buy | — | $8.75 | $8.72 | -0.3% | -0.6% | -4.5% | -3.6% | +7.6% | -1.5% |
| Jun 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.19 | $8.22 | +0.4% | +6.8% | -0.6% | -4.5% | -3.6% | +7.6% |
| Jun 4 | JP Morgan | Maintains | Overweight → Overweight | — | $9.88 | $9.88 | +0.0% | -6.7% | +6.2% | -5.3% | -1.8% | -0.2% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.09 | $12.20 | +0.9% | +1.1% | +1.9% | +3.9% | -3.2% | -5.4% |
| May 8 | Baird | Maintains | Outperform → Outperform | — | $11.87 | $11.87 | +0.0% | -2.6% | +9.6% | -4.6% | +1.1% | +1.9% |
| May 7 | Chardan Capital | Maintains | Buy → Buy | — | $11.20 | $11.20 | +0.0% | +6.0% | -2.6% | +9.6% | -4.6% | +1.1% |
| May 7 | Mizuho | Maintains | Buy → Buy | — | $11.20 | $11.20 | +0.0% | +6.0% | -2.6% | +9.6% | -4.6% | +1.1% |
| Mar 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.31 | $25.02 | -1.1% | -3.6% | -6.3% | -0.3% | -3.2% | -1.6% |
| Feb 16 | Mizuho | Maintains | Buy → Buy | — | $29.08 | $29.24 | +0.6% | -2.6% | -2.1% | -3.9% | -2.0% | +1.7% |
| Jan 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.76 | $22.09 | -2.9% | +0.0% | -3.9% | +4.5% | -2.4% | +7.4% |
| Dec 7 | Mizuho | Maintains | Buy → Buy | — | $19.35 | $20.16 | +4.2% | +9.5% | -9.6% | +4.3% | -4.9% | +7.8% |
| Dec 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.34 | $19.27 | +5.1% | -3.3% | +9.1% | +9.5% | -9.6% | +4.3% |
| Nov 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.24 | $7.60 | +5.0% | +0.7% | +6.3% | -1.5% | +0.3% | -8.6% |
| Sep 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $10.81 | $10.90 | +0.8% | +1.8% | -4.7% | -7.8% | -2.9% | -8.6% |
| Sep 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.65 | $11.65 | +0.0% | -3.3% | -4.1% | +1.8% | -4.7% | -7.8% |
| Aug 31 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $11.06 | $11.10 | +0.4% | -10.4% | +6.2% | -10.3% | +3.5% | +3.0% |
| Aug 3 | Chardan Capital | Maintains | Buy → Buy | — | $12.79 | $12.80 | +0.1% | -2.0% | +3.0% | -4.1% | +0.0% | +6.1% |
| Aug 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.79 | $12.80 | +0.1% | -2.0% | +3.0% | -4.1% | +0.0% | +6.1% |
| Jul 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.50 | $10.73 | +2.2% | +12.8% | +5.6% | +1.6% | +0.7% | -2.0% |
| Jun 28 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.66 | $7.65 | -0.1% | +2.7% | +4.4% | +5.8% | -6.9% | +6.5% |
| Jun 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.04 | $6.01 | -0.5% | +7.5% | -3.4% | -3.0% | -0.5% | +4.3% |
| May 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.13 | $6.44 | +5.1% | +6.0% | +6.0% | -2.9% | -6.3% | -5.4% |
| May 19 | Chardan Capital | Maintains | Buy → Buy | — | $6.13 | $6.44 | +5.1% | +6.0% | +6.0% | -2.9% | -6.3% | -5.4% |
| May 18 | Guggenheim | Maintains | Buy → Buy | — | $6.41 | $6.50 | +1.4% | -4.4% | +6.0% | +6.0% | -2.9% | -6.3% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.28 | $2.35 | +3.1% | +24.1% | +0.7% | +19.3% | -5.9% | -8.1% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.89 | $2.95 | +2.1% | +12.8% | -0.6% | -3.1% | -9.9% | -4.9% |
| Mar 3 | Chardan Capital | Maintains | Buy → Buy | — | $2.89 | $2.95 | +2.1% | +12.8% | -0.6% | -3.1% | -9.9% | -4.9% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.37 | $3.34 | -0.9% | -0.9% | -5.1% | -8.8% | +12.8% | -0.6% |
| Nov 11 | Guggenheim | Maintains | Buy → Buy | — | $4.66 | $4.69 | +0.6% | -0.6% | -1.1% | -3.5% | -7.5% | -8.6% |
| Aug 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.22 | $10.42 | +2.0% | +2.8% | +0.2% | +0.7% | +2.1% | +2.6% |
| Jul 7 | Chardan Capital | Maintains | Buy → Buy | — | $7.79 | $8.03 | +3.1% | +2.6% | +3.3% | -0.4% | -3.0% | +5.5% |
No insider trades available.
8-K · 2.02
!! High
EyePoint Pharmaceuticals, Inc. -- 8-K 2.02: Earnings Results
EyePoint Pharmaceuticals reported earnings results and financial condition updates in its latest quarterly disclosure, with full details available in the attached press release.
May 6
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
EyePoint faces potential delays in DURAVYU clinical development and FDA communications, which could postpone revenue generation and pressure the stock if timelines slip further.
Apr 13
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
This vague Regulation FD disclosure lacks substantive information, suggesting either routine compliance filing or delayed material news announcement that could trigger volatility once details emerge.
Mar 20
8-K
EyePoint, Inc. -- 8-K Filing
EyePoint maintains over $300 million in cash and investments as of December 31, 2025, extending its operational runway into Q4 2027 without immediate funding pressures.
Mar 4
8-K · 8.01
!! High
EyePoint, Inc. -- 8-K 8.01: Material Event / Announcement
EyePoint Pharmaceuticals achieved a clinical milestone by dosing first patients in both Phase 3 trials for DURAVYU, its diabetic macular edema treatment, advancing toward potential regulatory approval and commercialization.
Mar 2
Data updated apr 25, 2026 8:18am
· Source: massive.com